Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

NCT07585370 — Recruiting, 24740 participants, Jiangsu Province Centers for Disease Control and Prevention

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years or Older: a Multicenter, Retrospective Cohort Study Based on Phase III Trial

Registry	NCT07585370
Status	Recruiting
Study type	Observational
Enrollment	24740 (Estimated)
Sponsor	Jiangsu Province Centers for Disease Control and Prevention (Network); collaborators: Zhejiang Provincial Center for Disease Control and Prevention, Changxing County Center for Disease Control and Prevention (Changxing County Health Supervision Institute), Guanyun County Center for Disease Control and Prevention (Guanyun County Health Supervision Institute), Pizhou City Center for Disease Control and Prevention (Health Supervision Institute), Pei County Center for Disease Control and Prevention (Pei County Health Supervision Institute), Binhai County Center for Disease Control and Prevention (Binhai County Health Supervision Institute)
Conditions	Herpes Zoster
Interventions	Attenuated Zoster Vaccine, Live, Matched Placebo Without Live Virus (Biological)
Dates	start 2026-03-06, primary completion 2026-06-30 (estimated), completion 2026-06-30 (estimated), first posted 2026-05-13, last updated 2026-05-13
Locations	1 site in China

-Summary

This is a multicenter retrospective cohort study to evaluate the long-term effectiveness of the live attenuated herpes zoster vaccine within 6 years after vaccination. We plan to select 24,740 participants who were non-herpes zoster cases in the modified Full Analysis Set for Efficacy (E-mFAS) from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine manufactured by Changchun BCHT Biotechnology Co. conducted during 2020-2021. In the original Phase III Clinical Trial, the participants were randomly assigned to the vaccine group and the placebo group at a 1:1 ratio to receive one dose of the live attenuated herpes zoster vaccine (with varicella-zoster virus >=4.3 lg PFU per 0.5 mL dose) or one dose of placebo (with no varicella-zoster virus component), respectively. This study uses a stage-based design. In Stage 1, participants originally assigned to the vaccine group and those originally assigned to the placebo group will be compared to assess the cumulative incidence of herpes zoster from the end of the original Phase III Clinical Trial in July 2021 to the marketing authorization of the vaccine in China in June 2023. In Stage 2, after marketing authorization of the vaccine in China in June 2023, a large proportion of the participants originally assigned to the placebo group received catch-up vaccination and thereby formed a catch-up vaccination group. These stage-specific groups will be compared to evaluate the relative waning of protection in participants who received catch-up vaccination compared with participants vaccinated in the original Phase III Clinical Trial. In addition, among participants originally assigned to the placebo group who received catch-up vaccination, the incidence of herpes zoster during the post-catch-up vaccination period will be compared with the incidence during their earlier placebo period before catch-up vaccination, in order to evaluate the relative risk of herpes zoster under vaccinated versus placebo exposure. For this study, telephone surveys will be conducted using a standardized questionnaire to collect data on herpes zoster occurrence from participants, with verbal informed consent obtained prior to the survey. Face-to-face interviews will also be conducted to verify reported herpes zoster cases. Moreover, their past medical history and lifestyle information will be collected.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
The vaccine group.		Biological: Attenuated Zoster Vaccine, Live
The placebo group.		Biological: Matched Placebo Without Live Virus; Biological: Attenuated Zoster Vaccine, Live

Attenuated Zoster Vaccine, Live (Biological): This vaccine was produced by Changchun BCHT Biotechnology Co.
Matched Placebo Without Live Virus (Biological): This placebo was produced by Changchun BCHT Biotechnology Co. for use in the Phase III Clinical Trial.
Attenuated Zoster Vaccine, Live (Biological): After market authorization in June 2023, part of the participants originally assigned to placebo received catch-up vaccination with the marketed live attenuated herpes zoster vaccine produced by Changchun BCHT Biotechnology Co.

+Outcome measures

Primary outcomes

Incidence of Herpes Zoster comparing participants originally assigned to the vaccine group and participants originally assigned to the placebo group [From the end of the Phase III Clinical Trial in July 2021 to June 2023, before catch-up vaccination among placebo participants]

Secondary outcomes

Incidence of Herpes Zoster comparing participants in the original placebo group who received catch-up vaccination and participants originally assigned to the vaccine group under continued follow-up [From June 2023 to the survey date in 2026]
Incidence of Herpes Zoster among participants originally assigned to the placebo group, comparing the post-catch-up vaccination period with their earlier placebo period before catch-up vaccination [From July 2021 to June 2023 for the earlier placebo period, and from June 2023 to the survey date in 2026 for the post-catch-up vaccination period]

Other outcomes

Incidence of Herpes Zoster stratified by sex [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by age group [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by chronic disease history [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by immunosuppressive treatment history [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by alcohol use [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by smoking status [From July 2021 to the survey date in 2026]
Incidence of Herpes Zoster stratified by physical activity or physical labor [From July 2021 to the survey date in 2026]

+Eligibility

Sex: All, ages: 40 Years to any, accepts healthy volunteers

Inclusion Criteria:

1. Individuals included in the E-mFAS from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine produced by Changchun BCHT biotechnology Co. conducted during 2020-2021.
2. Individuals who were able to complete the study with verbal informed consent.

Exclusion Criteria:

1. Individuals who developed herpes zoster during the original Phase III Clinical Trial follow-up period.
2. Individuals who were known to have died before the retrospective study.

+Locations (1)

Facility	City	Country	Status
Jiangsu Provincial Center for Diseases Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)	Nanjing, Jiangsu	China	Recruiting

+Investigators

Pengfei Jin, Principal investigator, Jiangsu Provincial Center for Diseases Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)